Melatonin treatment in individuals with intellectual disability and chronic insomnia: a randomized placebo‐controlled study

Braam, Wiebe; Didden, Robert; Smits, Marcel G.; Curfs, Leopold

doi:10.1111/j.1365-2788.2007.01016.x

Cited by 51 publications

(57 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Short trials of melatonin (10 days to 4 weeks), consistently report statistically significant decreases in sleep onset latency by about 20-30 minutes. 3,4,5,6 Longer trials (3-72 months) also endorse shorter sleep latency over time. 7,8 …”

Section: Pharmacologic Studiesmentioning

confidence: 96%

“…Two studies, Braam et al (2008b) 3 and De Leersnyder et al (2012) 5 , reported a decrease in night awakenings but three other studies of children with ID did not report a significant reduction in night awakenings with melatonin treatment. 6,7,9 Unlike early reports of melatonin use 10 and studies of specific disorders/syndromes, only one of the reviewed studies of children with ID reported melatonin-related side effects (i.e., daytime somnolence and naps).…”

Section: Pharmacologic Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin Treatment in Children with Developmental Disabilities

Schwichtenberg

Malow

2015

Sleep Medicine Clinics

View full text Add to dashboard Cite

Melatonin is commonly recommended to treat sleep problems in children with developmental disabilities. However, relatively few studies document the efficacy and safety of melatonin in pediatric populations with developmental diagnoses. This chapter reviews recent studies of melatonin efficacy across a wide breadth of developmental disabilities. Overall, short treatment trials (1 week to 3 months) of melatonin were associated with a significant decrease in sleep onset latency time for each of the disorders reviewed, with one notable exception, tuberous sclerosis. In general, reported side effects were uncommon and mild in nature. Across disorders, additional research is needed to draw disability-specific conclusions. However, studies to date provide positive support for future trials that include larger groups of children with specific disabilities/syndromes.

show abstract

Section: Pharmacologic Studiesmentioning

confidence: 96%

Section: Pharmacologic Studiesmentioning

confidence: 99%

Melatonin Treatment in Children with Developmental Disabilities

Schwichtenberg

Malow

2015

Sleep Medicine Clinics

View full text Add to dashboard Cite

show abstract

“…However, pharmacological sleep treatments have limited safety and efficacy data for all pediatric patients, including children with DS 19–22 . In addition, associated side effect profiles may lead to parental reluctance to use prescription medication for treating sleep problems 10,23 .…”

mentioning

confidence: 99%

Use of Sleep Evaluations and Treatments in Children with Down Syndrome

Esbensen

Beebe

Byars

et al. 2016

J Dev Behav Pediatr

View full text Add to dashboard Cite

Objective To characterize practice patterns regarding sleep evaluation and intervention among children with Down syndrome (DS). Method Data were obtained from electronic health records from 2009–2013 for a retrospective cohort of 954 children with DS, ages 5–21 years during the time sampled. ICD-9 diagnoses were used to identify children with obstructive sleep apnea and/or behavioral sleep disturbances. Primary outcomes were confirmed by participation in an overnight diagnostic polysomnography (PSG) and/or documented provision of specified sleep interventions including positive airway pressure, otolaryngology (ENT) surgery, sleep medication and behavioral sleep therapy. Results Overall, 47.7% of children with DS had undergone PSG, 39.1% had diagnosed sleep problems, and of those diagnosed with sleep problems, 81.2% had received sleep intervention. Consistent with best practice clinical care, sleep treatments matched the diagnosed sleep problems. Age, gender, and race, but not body mass index, were associated with PSG completion rate and occurrence rates for ENT surgery and sleep medication usage. Body mass index was associated with obstructive sleep apnea. Conclusion Despite high rates of reported sleep problems in children with DS, less than half underwent PSG. Children diagnosed with sleep problems received treatment consistent with their sleep diagnosis. However, age and gender were associated with differential rates of treatment delivery that was incongruous with prevalence rates for diagnosed sleep problems. These findings underscore the importance of screening for sleep problems in children with DS, and referring for and providing appropriate targeted sleep interventions.

show abstract

“…There is also evidence that melatonin may be helpful in treating sleep problems in children with intractable epilepsy (16), neurodevelopmental disabilities (17)(18)(19), and with Angelman syndrome (20).…”

Section: Sleep-onset Association Typementioning

confidence: 99%